mProX™ Human GPR52 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryBased on this stable cell line, we also provide cell-based in vitro assays to evaluate the effects of your compounds or antibodies.
Product Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human GPR52 Stable Cell Line (S01YF-0923-PY167). Click the button above to contact us or submit your feedback about this product.
Jennifer (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Sarah (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The administration of c11 treatment led to a notable elevation in intracellular cAMP levels within the Cont-HepG2 group. However, this effect was noticeably subdued when applied to GPR52-KD HepG2 cells.
The impact of the GPR52 agonist known as c11 on cAMP synthesis in HepG2 cells subjected to GPR52 siRNA or control siRNA treatment was investigated, involving a sample size of three. The cAMP levels were normalized based on protein concentration. The obtained data represents the mean values with standard error of the mean indicated. Statistical significance was denoted as # (p < 0.05) and ## (p < 0.01) for comparisons against c11-untreated control siRNA-treated cells, using an unpaired Student's t-test. Additionally, * (p < 0.05) and ** (p < 0.01) were used to indicate significance in comparisons between control siRNA-treated cells with c11 treatment and their counterparts, employing the same statistical test.
Ref: Wada, Mitsuo, et al. "GPR52 accelerates fatty acid biosynthesis in a ligand-dependent manner in hepatocytes and in response to excessive fat intake in mice." Iscience 24.4 (2021).
Pubmed: 33796846
DOI: 10.1016/j.isci.2021.102260
Research Highlights
Power ME, et al. "The non-nutritive sweetener sucralose increases beta-arrestin signaling at the ." Canadian journal of physiology and pharmacology, 2023.
In recent years, there has been a rise in the use of non-nutritive sweeteners in food products due to their low caloric content and strong sweetness compared to natural sugars. Despite evidence supporting their safety, there are studies contradicting this, suggesting that sweeteners may have negative effects on metabolism through unknown mechanisms. The authors propose that these sweeteners activate specific G protein-coupled receptors (GPCRs), particularly orphan receptors found in metabolically active tissues. Through a beta-arrestin-2 recruitment assay, the response of 64 orphan receptors to the sweeteners sucralose and saccharin was measured. It was found that GPR52 was the only receptor that significantly responded to the mixture of both sweeteners, with subsequent experiments revealing sucralose as the activating sweetener. This activation was concentration-dependent and did not further activate the receptor's CRE pathway, which is known to be constitutively active. This novel interaction between sucralose and GPR52 raises questions about the assumed lack of biological activity of sucralose, indicating the potential for off-target signaling through the activation of GPR52.
Pubmed:
37748201
DOI:
10.1139/cjpp-2023-0199
Wu Z, et al. "Dynamic Insights into the Self-Activation Pathway and Allosteric Regulation of ." Journal of chemical information and modeling, 2023.
The subject of this abstract explored the mechanism of action for orphan G-protein-coupled receptor 52 (GPR52), which has been identified as a promising therapeutic target for central nervous system disorders. Through 6 mus Gaussian accelerated molecular dynamics (GaMD) simulations, the receptor demonstrated a self-activation pathway in which it transitions from an active state to a matching inactive crystal structure. The results also revealed the allosteric regulation between the extracellular orthosteric binding pocket and the intracellular G-protein-binding site, identifying key microswitch residues and the allosteric communication pathway. The role of ECL2 in this allosteric regulation was further supported by transfer entropy calculations. Overall, this work provides a detailed atomic-level understanding of the self-activation of GPR52, shedding light on a potential target for novel drug development.
Pubmed:
37651308
DOI:
10.1021/acs.jcim.3c00672